WO2023207615A1 - Classe de composés d'arni double brin comportant un débordement constitué de nucléotides naturels - Google Patents

Classe de composés d'arni double brin comportant un débordement constitué de nucléotides naturels Download PDF

Info

Publication number
WO2023207615A1
WO2023207615A1 PCT/CN2023/088123 CN2023088123W WO2023207615A1 WO 2023207615 A1 WO2023207615 A1 WO 2023207615A1 CN 2023088123 W CN2023088123 W CN 2023088123W WO 2023207615 A1 WO2023207615 A1 WO 2023207615A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
double
present
nucleotides
stranded
Prior art date
Application number
PCT/CN2023/088123
Other languages
English (en)
Chinese (zh)
Inventor
贺海鹰
陆剑宇
胡彦宾
陈实
吴孝琴
石璐
胡利红
丁照中
Original Assignee
南京明德新药研发有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京明德新药研发有限公司 filed Critical 南京明德新药研发有限公司
Publication of WO2023207615A1 publication Critical patent/WO2023207615A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Abstract

L'invention concerne un composé d'ARNi double brin, en particulier une classe de composés d'ARNi double brin comportant un débordement constitué de nucléotides naturels.
PCT/CN2023/088123 2022-04-26 2023-04-13 Classe de composés d'arni double brin comportant un débordement constitué de nucléotides naturels WO2023207615A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210452045 2022-04-26
CN202210452045.7 2022-04-26

Publications (1)

Publication Number Publication Date
WO2023207615A1 true WO2023207615A1 (fr) 2023-11-02

Family

ID=88517438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/088123 WO2023207615A1 (fr) 2022-04-26 2023-04-13 Classe de composés d'arni double brin comportant un débordement constitué de nucléotides naturels

Country Status (1)

Country Link
WO (1) WO2023207615A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835789A (zh) * 2007-08-27 2010-09-15 波士顿生物医药公司 不对称干扰rna的组合物及其用途
US20160376585A1 (en) * 2013-07-11 2016-12-29 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US20170137808A1 (en) * 2014-03-20 2017-05-18 Oommen Varghese Improved small interfering ribonucleic acid molecules
US20200339991A1 (en) * 2018-12-19 2020-10-29 Alnylam Pharmaceuticals, Inc. AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
CN113166759A (zh) * 2018-12-10 2021-07-23 美国安进公司 经化学修饰的RNAi构建体及其用途
WO2021231827A2 (fr) * 2020-05-15 2021-11-18 Life Technologies Corporation Séquences d'arnsi ciblant le coronavirus-2
CN113795581A (zh) * 2019-05-03 2021-12-14 迪克纳制药公司 具有缩短的有义链的双链核酸抑制剂分子

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835789A (zh) * 2007-08-27 2010-09-15 波士顿生物医药公司 不对称干扰rna的组合物及其用途
US20160376585A1 (en) * 2013-07-11 2016-12-29 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US20170137808A1 (en) * 2014-03-20 2017-05-18 Oommen Varghese Improved small interfering ribonucleic acid molecules
CN113166759A (zh) * 2018-12-10 2021-07-23 美国安进公司 经化学修饰的RNAi构建体及其用途
US20200339991A1 (en) * 2018-12-19 2020-10-29 Alnylam Pharmaceuticals, Inc. AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF
CN113795581A (zh) * 2019-05-03 2021-12-14 迪克纳制药公司 具有缩短的有义链的双链核酸抑制剂分子
WO2021231827A2 (fr) * 2020-05-15 2021-11-18 Life Technologies Corporation Séquences d'arnsi ciblant le coronavirus-2

Similar Documents

Publication Publication Date Title
TW201219570A (en) Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
US11732262B2 (en) Use of FUBP1 inhibitors for treating hepatitis B virus infection
JP2021529525A (ja) Ｔａｕ発現調節用オリゴヌクレオチド
JP2021072862A (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
JP2021511029A (ja) Ｓｒｅｂｐ１を標的とするアンチセンスオリゴヌクレオチド
AU2021288648A1 (en) Conjugate of double-stranded siRNA analogue
KR20200104302A (ko) 신규 티오포스포르아미다이트
CN115884984A (zh) 用于治疗肝纤维化的结合物和方法
KR20220150881A (ko) 핵산 및 반감기 연장 모티프를 포함하는 화합물
WO2023207615A1 (fr) Classe de composés d'arni double brin comportant un débordement constitué de nucléotides naturels
WO2023155909A1 (fr) Analogue de ribavirine et son utilisation comme groupe d'enrobage
US20220031730A1 (en) Enhanced oligonucleotides for modulating fubp1 expression
WO2023208128A1 (fr) Conjugué d'analogue d'arni double brin contenant un analogue de nucléotide
JP2021533118A (ja) ホスホロトリチオアートヌクレオシド間結合を含むオリゴヌクレオチド
WO2024099316A1 (fr) Groupe de conjugaison tétravalent contenant un cycle hétérocyclique à sept chaînons et son utilisation
CN112513062B (zh) 含有寡聚核苷酸的小细胞肺癌治疗药
WO2023208106A1 (fr) Composé ayant un effet d'administration ciblant le foie et conjugué oligonucléotidique de celui-ci
JP2002511384A (ja) 新規な三重らせん形成性オリゴヌクレオチドおよび抗−ｈｂｖにおけるそれらの使用
WO2021249484A1 (fr) Groupe conjugué et conjugué
EP3919618A1 (fr) Molécule oligonucléotidique et son application en thérapie antitumorale
TW202102516A (zh) 膦醯基乙酸酯間隙子寡核苷酸
JP2022521512A (ja) 新規ホスホルアミダイト
US20210095276A1 (en) Oligonucleotides for modulating erc1 expression
CN112513062A (zh) 含有寡聚核苷酸的小细胞肺癌治疗药
JP2023528966A (ja) 二本鎖ｓｉＲＮＡ類似体のコンジュゲート

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23795048

Country of ref document: EP

Kind code of ref document: A1